Phenylpyrrole derivative

A method for treatment of dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, depression, or allergic rhinitis, the method comprising administering to a subject in need of said treatment, an effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

• [wherein
• Q refers to a group represented by the following formula (A) or (B):
• R1 is hydroxyl, C1-C6 alkoxy, or NR1A R1B;
• R1A and R1B, which may be the same or different, are each a hydrogen atom, C1-C6 alkyl or C3-C7 cycloalkyl, or
• R1A and R1B are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C1-C6 alkyls);
• R2 is a hydrogen atom, a halogen atom, or C1-C6 alkyl;
• n is 1 or 2;
• R3 is a hydrogen atom, a halogen atom, or C1-C6 alkyl;
• R4 is C1-C6 alkyl (the C1-C6 alkyl may be substituted by one or two C3-C7 cycloalkyls) or C3-C7 cycloalkyl (the C3-C7 cycloalkyl may be substituted by one or two C1-C6 alkyls);
• R5 and R6, which may be the same or different, are each C1-C6 alkyl or C3-C7 cycloalkyl, or
• R5 and R6 are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C1-C6 alkyls)].

A method of antagonizing histamine H3 receptor, the method comprising administering to a subject in need thereof, an effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound or salt thereof is a histamine H3 receptor antagonist or inverse agonist

• [wherein
• Q refers to a group represented by the following formula (A) or (B):
• R1 is hydroxyl, C1-C6 alkoxy, or NR1A R1B;
• R1A and R1B, which may be the same or different, are each a hydrogen atom, C1-C6 alkyl or C3-C7 cycloalkyl, or
• R1A and R1B are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C1-C6 alkyls);
• R2 is a hydrogen atom, a halogen atom, or C1-C6 alkyl;
• n is 1 or 2;
• R3 is a hydrogen atom, a halogen atom, or C1-C6 alkyl;
• R4 is C1-C6 alkyl (the C1-C6 alkyl may be substituted by one or two C3-C7 cycloalkyls) or C3-C7 cycloalkyl (the C3-C7 cycloalkyl may be substituted by one or two C1-C6 alkyls);
• R5 and R6, which may be the same or different, are each C1-C6 alkyl or C3-C7 cycloalkyl, or
• R5 and R6 are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C1-C6 alkyls)].